Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD2 | O14939 | 20/20 | 1.00 |
| ▸ | PLD1 | Q13393 | 18/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14845990 | 0.94 | PLD2 (1.00) | PLD2PLD1DRD2 | |
| SCHEMBL14845950 | 0.93 | PLD2 (1.00) | PLD2PLD1DRD2 | |
| SCHEMBL11721488 | 0.91 | PLD2 (1.00) | PLD2PLD1DRD2 | |
| SCHEMBL11718009 | 0.90 | PLD2 (0.82) | PLD2PLD1DRD2 | |
| SCHEMBL11716325 | 0.89 | PLD2 (1.00) | PLD2PLD1DRD2 | |
| SCHEMBL14845956 | 0.89 | PLD2 (1.00) | PLD2PLD1DRD2 | |
| SCHEMBL11713881 | 0.89 | PLD2 (0.86) | PLD2PLD1DRD2 | |
| SCHEMBL11716282 | 0.89 | PLD2 (0.79) | PLD2PLD1DRD2 | |
| SCHEMBL14845947 | 0.87 | PLD2 (1.00) | PLD2PLD1DRD2 | |
| SCHEMBL11721537 | 0.87 | PLD2 (0.77) | PLD2PLD1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 474 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117731784-A | Pharmaceutical composition for preventing or reversing drug resistance to BRAVV 600E mutant melanoma | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 2024-03-22 | — | — | CN | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-20170319611-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | UNIV VANDERBILT (US) | 2017-11-09 | — | — | US | claimed |
| US-20160271114-A1 | Composition for preventing or treating bacterial infectious disease comprising phospholipase D2 inhibitor | Research & Business Foundation Sungkyunkwan University (KR) | 2016-09-22 | — | — | US | claimed |
| US-9267122-B2 | Modulation of phospholipase D for the treatment of neurodegenerative disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-02-23 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20150025041-A1 | ANTIVIRAL THERAPIES WITH PHOSPHOLIPASE D INHIBITORS | VANDERBILT UNIVERSITY (US) | 2015-01-22 | — | — | US | claimed |
| EP-2760447-A1 | ANTIVIRAL THERAPIES WITH PHOSPHOLIPASE D INHIBITORS | Vanderbilt University (US) | 2014-08-06 | — | — | EP | claimed |
| US-20130273620-A1 | METHODS FOR ALTERING LIPIDS IN ALGAE AND YEAST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-10-17 | — | — | US | claimed |
| WO-2013138523-A1 | METHODS FOR ALTERING LIPIDS IN ALGAE AND YEAST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-09-19 | — | — | WO | claimed |
| WO-2007036671-A2 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME | FLAMEL TECHNOLOGIES (FR) | 2007-04-05 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1044023-B1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | LUITPOLD PHARM INC (US) | 2005-05-25 | — | — | EP | claimed |
| US-6197764-B1 | COMPLEX WITH FATTY ACID; THERAPY FOR PSYCHOLOGICAL DISORDERS | PROTARGA, INC. | 2001-03-06 | — | — | US | claimed |
| EP-1044023-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | Protarga Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | claimed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | claimed |
| US-4031226-A | ANTIEMETIC, PSYCHOTROPIC | JANSSEN PHARMACEUTICA N.V. (BE) | 1977-06-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170319611-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | PLD1, PLD2, PIK3CD | PLD2 2/4885PLD1 1/4885DRD2 909/4885 |
| US-20150025041-A1 | ANTIVIRAL THERAPIES WITH PHOSPHOLIPASE D INHIBITORS | PLD1, PLA2G2D, PLD2 | PLD2 3/4885PLD1 1/4885DRD2 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.